Table 4.
In vitro anticancer activity and molecular docking of selected synthesized compounds.
| Compounds | GI50 Against Cancer Cell Line in µM | Total Score -Logki | Crash Score | Polar Score | |||
|---|---|---|---|---|---|---|---|
| MAD-MB-231 | HeLa | SK-MEL-2 | K-562 | ||||
| 5b | 0.74 | >100 | <0.1 | 11.2 | 6.4039 | −0.9801 | 2.0598 |
| 5d | 25.76 | >100 | <0.1 | 6.41 | 5.4734 | −1.3871 | 4.449 |
| 5g | 2.02 | >100 | 2.92 | 40.73 | 4.6919 | −0.4209 | 5.4948 |
| 5h | 49.84 | >100 | 0.12 | 4.57 | 4.5247 | −0.184 | 3.7291 |
| 5j | 66.65 | >100 | <0.1 | 9.47 | 4.6555 | −0.7369 | 3.5549 |
| ADR | <0.1 | 0.03 | <0.1 | <0.1 | NA | NA | NA |
| CL2 | NA | NA | NA | NA | 5.1969 | −0.8748 | 3.5552 |
CL2: Co-crystallized ligand and Adriamycin (ADR), the standard drug used for the anticancer activity assays.